Understanding changes in cholinergic function: implications for treating dementia.
D000203:Activities of Daily Living; D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy; D002219:Carbamates / Q000627:therapeutic use*; D002799:Cholinergic Fibers / Q000187:drug effects*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003704:Dementia / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D020961:Lewy Body Disease / Q000150:complications / Q000188:drug therapy; D001523:Mental Disorders / Q000209:etiology / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy; D048448:Phenylcarbamates; D000068836:Rivastigmine; D012720:Severity of Illness Index; D016896:Treatment Outcome
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine